MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
21.34
-0.37
-1.70%
After Hours: 21.76 +0.42 +1.97% 19:55 03/13 EDT
OPEN
21.94
PREV CLOSE
21.71
HIGH
22.27
LOW
21.29
VOLUME
2.54M
TURNOVER
--
52 WEEK HIGH
42.37
52 WEEK LOW
18.41
MARKET CAP
2.06B
P/E (TTM)
-3.6594
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These Healthcare Names: Immutep (IMMP) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 1d ago
Weekly Buzz: BMY Wins FDA Nod; EU Okays JNJ's AKEEGA; IPSEY Withdraws Tazverik, DAWN Acquired
NASDAQ · 2d ago
DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
PR Newswire · 2d ago
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
NASDAQ · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN)
TipRanks · 2d ago
Ultragenyx Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
Ultragenyx Pharma Price Target Cut to $74.00/Share From $120.00 by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $74
Benzinga · 3d ago
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.